Pulmonary edema as an adverse effect in Albumin Treatment for Acute Ischemic Stroke Study (ALIAS) [abstract] Abstract uri icon
  • Background: Acute Pulmonary Edema is one of the important adverse effects seen in patients in Albumin Treatment In Acute Ischemic Stroke (ALIAS) study. There has been little consensus in relation to this adverse effect. Methods: We retrospectively collected the data from ALIAS I & II database and tried to compare by dichotomizing patients of acute pulmonary edema in the study with non-pulmonary edema cases. All the demographic particulars, co-morbidities, outcomes in the form of National Institute of Health Stroke Scale (NIHSS) and Modified Rankin Scale (mRS) along with other adverse effects like pneumonia, Myocardial infarction and arrhythmias were compared. Results: We analyzed 1275 patients in both ALIAS I&II studies looking for adverse effect of pulmonary edema.Out of 1275 patients, 45 (3.5[percnt]) have pulmonary edema. The mean age among patients having this adverse effect is 63.25 ± 16.53 years with Men (28.8[percnt]) and women (71.1[percnt]). The mean NIHSS among Pulmonary edema cases was 6.56 ± 6.5. The favourable outcome mRS (0-2) were only 7 patients. The mean systolic Blod pressure seen among them is 138.63 ± 23.27 (mmHg). The mean creatinine level was 78.23 ± 15.70 (umol/L). Conclusion: We did not find any significant association of pulmonary edema as an adverse effect with non-pulmonary edema. Further analysis is needed to look for any significant association.

  • publication date
  • 2016
  • published in
  • Neurology  Journal
  • Research
  • Drugs and Drug Therapy
  • Lung Diseases
  • Stroke
  • Additional Document Info
  • 86
  • issue
  • 16 Suppl